Last edition
News about Global Pharma
Aptar Pharma Files Patents, Reports Positive Preclinical Data for GLP-1 Nasal and Pulmonary Delivery
Aptar Pharma announced new patent applications and positive preclinical data supporting intranasal and pulmonary GLP-1 delivery, expanding its capabilities in inhaled and intranasal biologic drug delivery.
Global Pharma | 29/05/2026 | By News Bureau
Eli Lilly and Company reports that a single dose of investigational gene-editing therapy VERVE-102 delivered sustained reductions in PCSK9 and LDL cholesterol for up to 18 months in high-risk cardiovascular patients.
Global Pharma | 26/05/2026 | By News Bureau | 217
AbbVie Receives Positive CHMP Opinion for MAVIRET in Acute Hepatitis C Treatment
AbbVie receives a positive CHMP opinion for MAVIRET to treat acute hepatitis C, supported by Phase 3 data demonstrating safety and efficacy in adults with acute HCV infection.
Global Pharma | 26/05/2026 | By News Bureau
Venus Remedies Secures Saudi FDA Approval for Plerixafor Oncology Therapy
Venus Remedies receives Saudi FDA approval for Plerixafor, marking its first global marketing authorisation for the specialty oncology therapy used in stem cell mobilisation for multiple myeloma and non-Hodgkin lymphoma patients undergoing autologous transplantation.
Global Pharma | 25/05/2026 | By News Bureau
Gilead Sciences and Kite Pharma to present new ASCO and EHA 2026 data highlighting progress in Antibody Drug Conjugates (ADCs) and CAR T-cell therapies, including updates on Trodelvy and anito-cel for difficult-to-treat cancers.
Global Pharma | 22/05/2026 | By News Bureau | 346
Emiltatug Ledadotin Wins FDA Breakthrough Tag for Adenoid Cystic Carcinoma
Emiltatug Ledadotin receives U.S. Food and Drug Administration Breakthrough Therapy designation for adenoid cystic carcinoma, a potentially innovative and differentiated Antibody Drug Conjugate (ADC) directed against B7-H4, a well-characterised target in certain cancers including ACC.
Global Pharma | 13/05/2026 | By News Bureau
Onco-Innovations Subsidiary Partners with GSK on Real-World Oncology Data Research
Inka Health and GSK will collaborate to develop real-world data methodologies aimed at improving the applicability of oncology clinical trial findings across diverse patient populations and healthcare settings.
Global Pharma | 07/05/2026 | By News Bureau
Cellenkos Receives US FDA IND Clearance for CK0802 Phase 1b/ 2a Trial in GVHD
The US Food and Drug Administration (FDA) clears Cellenkos Inc IND for CK0802, a first-in-class off-the-shelf Treg therapy, advancing to a phase 1b/2a trial in steroid-refractory Graft-Versus-Host Disease (GVHD).
Global Pharma | 06/05/2026 | By News Bureau
Incyte Wins US FDA Approval for Jakafi XR (Ruxolitinib)
The US Food and Drug Administration (FDA) approves Incyte Corporation’s Jakafi XR (ruxolitinib), a once-daily extended-release tablet for myelofibrosis, polycythemia vera and GVHD, offering consistent day-long exposure.
Global Pharma | 02/05/2026 | By News Bureau | 153
Arrowhead Pharmaceuticals Wins Australia TGA Approval for REDEMPLO
Arrowhead Pharmaceuticals receives TGA approval for REDEMPLO (plozasiran) in Australia, the first treatment for Familial Chylomicronemia Syndrome (FCS), backed by phase 3 data showing significant triglyceride reduction and lower pancreatitis risk.
Global Pharma | 01/05/2026 | By News Bureau | 135
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy